MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Neothetics Company Profile (NASDAQ:NEOT)

Consensus Ratings for Neothetics (NASDAQ:NEOT) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $16.00 (1,548.30% upside)

Analysts' Ratings History for Neothetics (NASDAQ:NEOT)
Show:
DateFirmActionRatingPrice TargetActions
12/15/2015Piper JaffrayDowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015GuggenheimReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Neothetics (NASDAQ:NEOT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($1.14)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.84)($1.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($1.14)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.93)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.32)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Neothetics (NASDAQ:NEOT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Neothetics (NASDAQ:NEOT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Neothetics (NASDAQ:NEOT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/30/2015Alta Partners Viii, L.P.InsiderSell797,987$1.51$1,204,960.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Alta Partners Viii, L.P.Major ShareholderSell493,654$1.53$755,290.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Alta Partners Viii, L.P.Major ShareholderSell54,333$1.59$86,389.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Kenneth W. LockeInsiderSell598$1.26$753.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Susan A. KnudsonCFOSell1,005$1.26$1,266.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Alta Partners Viii, L.P.Major ShareholderSell529,261$1.44$762,135.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Kenneth W. LockeinsiderSell6,098$8.30$50,613.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Christopher KemmererVPSell1,000$12.20$12,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Susan A. KnudsonCFOSell3,000$11.33$33,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015George W MahaffeyCEOBuy1,000$7.76$7,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Daniel JanneyDirectorSell149,286$14.00$2,090,004.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Rmi Investments S.A.R.L.Major ShareholderBuy70,000$14.00$980,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Neothetics (NASDAQ:NEOT)
DateHeadline
06/19/16 09:23 AMNEOTHETICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/17/16 07:01 AMNEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/06/16 07:01 AMNEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; -
05/30/16 06:20 PMNeothetics, Inc. (NEOT) Broker Price Targets For The Coming Week - Share Trading News - Neothetics, Inc. (NEOT) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Neothetics, Inc. (NEOT). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Neothetics Incorporated (NASDAQ:NEOT) Shorted Shares Increased By 21.75%HNNall 3 news articles »
05/12/16 07:13 AMNeothetics reports 1Q loss -
05/12/16 07:07 AMNeothetics Reports First Quarter 2016 Financial Results - [at noodls] - SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today reported financial results and business progress for the first quarter 2016. ... This is an abstract of the original noodl. ...
05/12/16 07:01 AMNEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/12/16 06:07 AMQ1 2016 Neothetics Inc Earnings Release - Before Market Open -
05/05/16 07:21 AMNeothetics to Release First Quarter 2016 Financial Results - [at noodls] - SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will ...
04/25/16 10:30 AMStocks To Watch: Investors Are Considering These on Monday April 25th - [Accesswire] - MIAMI, FL / ACCESSWIRE / April 25, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. NEOT, MCUR, TPUB, and LGCY have been added to our watch list today. Continue reading to find out ...
02/18/16 03:08 PMNEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal -
02/18/16 03:00 PMNeothetics Announces Leadership Change and Preliminary Update on LIPO-202 - [GlobeNewswire] - SAN DIEGO, Feb. 18, 2016-- Neothetics, Inc., a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey offered his resignation ...
01/17/16 06:54 PMSpeaker: Combining peels with other procedures ‘safe’, easy, inexpensive - Disclosure: Kaufman reports she has financial interest with Allergan, Galderma, Elizabeth Arden, Energizer, Glisodin, Lutronic, Merz, Alphaeon, Cosmetic Dermatology Inc., Cutera, Neothetics, Revance, Teoxane and Valeant Pharmaceuticals.
12/23/15 03:47 PMNEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
12/15/15 12:15 PMWhy Neothetics Is Getting Destroyed -
12/14/15 04:54 PMBreaking: This Biotech Just Got Blown Up on a Late Stage Trial -
12/14/15 04:02 PMNEOTHETICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
12/14/15 03:39 PMNeothetics Reports LIPO-202 Top-Line Phase 3 Trial Results for the Reduction of Central Abdominal Bulging - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:NEOT) today announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction ...
12/10/15 03:39 PMNEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
12/08/15 12:17 PMNEOTHETICS, INC. Financials -
12/07/15 07:24 AMNeothetics Announces Issuance by USPTO of Fourth Patent Directed to LIPO-202 Lead Clinical Asset - [at noodls] - SAN DIEGO, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance ...
12/01/15 04:21 PMNEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
12/01/15 06:43 AMNeothetics Tightens Guidance for Timing of Top-Line Pivotal Phase 3 Data - [at noodls] - SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today tightened its guidance ...
About Neothetics

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company. The Company develops therapeutics for the aesthetic market. The Company's initial focus is on localized fat reduction and body contouring. The Company's lead product candidate LIPO-202 is an injectable treatment for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is also developing another product candidate LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NEOT
  • CUSIP:
Key Metrics:
  • Previous Close: $0.97
  • 50 Day Moving Average: $1.1305
  • 200 Day Moving Average: $1.2514
  • P/E Ratio: N/A
  • P/E Growth: -0.0200
  • Market Cap: $13.39M
  • Current Quarter EPS Consensus Estimate: $-2.2400 EPS
Additional Links:
Neothetics (NASDAQ:NEOT) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha